Anavex Life Sciences Corp (AVXL)

[abew4me]

Excellent points, falconer.

"Aricept is already a minor Alzheimer' drug of little repute. One doesn't hear of Aricept successes. There are none. The same story will be said of the new Biogen drug — should it ever get approved."

And frankly, we won't be going head-to-head with them until we get our P2b/3 results next year anyway.

At this point, Anavex is laser-focused on commercializing A2-73 for the rare disease communities...such as Rett, Fragile X, etc.

This is very important because it will change our status from a baby biotech with no revenue...to a respected biotech company that is generating income from several different maladies.

This strategic plan makes it much easier for the FDA to approve A2-73 for Alzheimer's once we submit the results from our P2b/3 study next year...assuming we have excellent results, of course.